Global RNA-interference (RNAi) Market Segmented by Application - Analysis, Growth, Trends & Forecast 2018-2023 - ResearchAndMarkets.com

DUBLIN--()--The "Global RNA-interference (RNAi) Market - Segmented by Application - Growth, Trends, and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.

The RNAi market is expected to witness a CAGR of 20.2% during the forecast period. North America dominates the global market due to high incidence of genetic and metabolic disorders.

Cancer diagnosis and treatment is currently undergoing a paradigm shift with the incorporation of RNAi techniques in personalized medicines and molecular diagnostics. The availability of high throughput techniques for the identification of altered cellular molecules and metabolites allows the use of RNAi techniques in various cancer diagnosis and targeting approaches. For diagnostics purposes, small interfering RNAs (siRNA) or microRNAs (miRNA) can be utilized, and commercial availability of siRNAs to silence virtually any gene in the human genome is dramatically accelerating the pace of molecular diagnosis and biomedical research.

There has been a decline in the FDA drug approval rates. Getting FDA approval for a new drug has become extremely challenging. It had approved less than half the number of new drugs in 2016 (19 so far), when compared to 2015 (45 total) and 2014 (41 total). Hence, despite the large investments, there has been a decline in the number of innovative drugs manufactured.

North America, especially the United States, holds the largest market share of the RNAi market. There are a large number of companies and research institutes in the country with a huge amount being invested in research on drug discovery using RNAi technology; the recent technological and medical advances are available in North America. Other factors, such as growing population and high incidence of diseases, such as liver disorders and cancers, are fuelling the regional growth of this market.

Companies Mentioned

  • Alnylam Pharmaceuticals
  • Quark Pharmaceuticals Inc.
  • Benitec Biopharma Ltd
  • ISIS Pharmaceuticals
  • RXI Pharmaceuticals
  • Filmtec Corporation
  • Silence Therapeutics
  • MERCK
  • Tekmira Pharmaceuticals Corporation
  • Qiagen
  • Invitrogen
  • Ambion

Key Topics Covered:

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

6. Drivers, Restraints, Opportunities And Challenges Analysis (DROC)

7. Market Segmentation

8. Competitive Landscape

9. Key Players

10. Future Outlook of the Market

For more information about this report visit https://www.researchandmarkets.com/research/q84xdb/global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Genomics

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Genomics